Mesoblast Limited

Mesoblast Limited is a biotechnology company focused on developing regenerative medicine products. Its proprietary technology platform is based on specialized cells called mesenchymal lineage cells. The company has a pipeline of product candidates targeting various diseases. Its lead candidate, Remestemcel-L, is in Phase III clinical trials for systemic inflammatory diseases such as steroid refractory acute graft versus host disease (SR-aGVHD) and biologic refractory inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Additionally, Remestemcel-L is being studied for chronic heart failure and chronic low back pain due to degenerative disc disease. Other candidates include MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy, and MPC-150-IM for chronic heart failure, developed in partnership with Tasly Pharmaceutical Group. Mesoblast also has programs for acute myocardial infarction, wound healing in epidermolysis bullosa, and neonatal hypoxic ischemic encephalopathy through collaborations with JCR Pharmaceuticals and Grünenthal.

Mesoblast Limited is listed on the Nasdaq Global Select Market under the ticker symbol MESO. The company's shares trade in US Dollars (USD). This listing provides Mesoblast with access to a broad base of international investors, particularly in the United States, which is a key market for its clinical development and potential commercialization efforts. The company is headquartered in Melbourne, Australia, but its Nasdaq listing reflects its strategic focus on the US healthcare market.

Mesoblast operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using regenerative medicine. Its work involves advanced cell-based technologies, particularly mesenchymal lineage cells, to address serious diseases with high unmet medical needs. The biotechnology industry is characterized by intensive research and development, lengthy clinical trial processes, and regulatory approvals. Mesoblast's pipeline includes treatments for inflammatory, cardiovascular, and degenerative conditions, placing it at the forefront of cell therapy innovation.

Mesoblast Limited is headquartered in Melbourne, Australia, and was incorporated in 2004. The company operates in Australia, the United States, Singapore, and Switzerland. Its primary focus is on developing and commercializing regenerative medicine products globally. The United States is a key market, as evidenced by its Nasdaq listing and clinical trials for conditions like SR-aGVHD and chronic heart failure. Mesoblast also has strategic partnerships with companies such as Tasly Pharmaceutical Group in China and Grünenthal in Europe, indicating a broad geographic reach. Its products target patients with inflammatory, cardiovascular, and degenerative diseases across multiple regions.

Mesoblast's main product candidates include Remestemcel-L, which is in Phase III trials for steroid refractory acute graft versus host disease (SR-aGVHD), biologic refractory inflammatory bowel disease, chronic heart failure, and chronic low back pain. Another candidate, MPC-300-IV, targets biologic refractory rheumatoid arthritis and diabetic nephropathy. The company also has MPC-150-IM for chronic heart failure, developed with Tasly Pharmaceutical Group. Additionally, its portfolio includes MPC-25-IC for acute myocardial infarction, Ryoncil for pediatric SR-aGVHD, and programs with JCR Pharmaceuticals for wound healing in epidermolysis bullosa and neonatal hypoxic ischemic encephalopathy. Mesoblast has a partnership with Grünenthal to develop and commercialize cell therapy for chronic low back pain. These collaborations help advance its pipeline and expand its global reach.